| | |
2002 baseline data, divided by MetS outcome in 2007**
| |
|---|
|
Abnormality Prevalence*
|
Overall N = 1384
|
Without MetS outcome n = 1209
|
With MetS outcome, n = 175
|
P
|
|---|
|
MetS component (not segregated)
| | | | |
|
COB
|
54 (3.9%)
|
28 (2.3%)
|
26(14.9%)
|
<0.01
|
|
Hyper-GL
|
284 (20.5%)
|
234 (19.4%)
|
50(28.6%)
|
0.01
|
|
HBP
|
245 (17.7%)
|
193 (16.0%)
|
52(29.7%)
|
<0.01
|
|
Low-HDL
|
338 (24.4%)
|
269 (22.2%)
|
69(39.4%)
|
<0.01
|
|
Hyper-TG
|
190 (13.7%)
|
139 (11.5%)
|
51(29.1%)
|
<0.01
|
|
MetS component (segregated by count and combination)
| | | | |
|
Single component
|
511 (36.9%)
|
451 (37.3%)
|
60 (34.3%)
|
0.44
|
|
Hyper-GL alone
|
149 (10.8%)
|
132 (10.9%)
|
17(9.7%)
|
0.62
|
|
Low-HDL alone
|
168 (12.1%)
|
151 (12.5%)
|
17(9.7%)
|
0.27
|
|
HBP alone
|
115 (8.3%)
|
107 (8.9%)
|
8(4.6%)
|
0.02
|
|
Hyper-TG alone
|
63 (4.6%)
|
51 (4.2%)
|
12(6.9%)
|
0.19
|
|
COB alone
|
16 (1.2%)
|
10 (0.8%)
|
6(3.4%)
|
0.07
|
|
Two components
|
300 (21.7%)
|
206 (17.0%)
|
94 (53.7%)
|
<0.01
|
|
Low-HDL-plus-Hyper-TG
|
61 (4.4%)
|
43 (3.6%)
|
18(10.3%)
|
<0.01
|
|
Hyper-GL-plus-Low-HDL
|
51 (3.7%)
|
42 (3.5%)
|
9(5.1%)
|
0.34
|
|
Low-HDL-plus-HBP
|
42 (3.0%)
|
26 (2.2%)
|
16(9.1%)
|
<0.01
|
|
Hyper-TG-plus-HBP
|
31 (2.2%)
|
22 (1.8%)
|
9(5.1%)
|
0.05
|
|
Hyper-GL-plus-Hyper-TG
|
30 (2.2%)
|
22 (1.8%)
|
8(4.6%)
|
0.09
|
|
COB-plus-Low-HDL
|
16 (1.2%)
|
7 (0.6%)
|
9(5.1%)
|
<0.01
|
|
COB-plus-HBP
|
10 (0.7%)
|
5 (0.4%)
|
5(2.9%)
|
0.06
|
|
COB-plus-Hyper-GL
|
7 (0.5%)
|
5 (0.4%)
|
2(1.1%)
|
0.38
|
|
COB-plus-Hyper-TG
|
5 (0.4%)
|
1 (0.1%)
|
4(2.3%)
|
0.05
|
- * The abnormality prevalence is demonstrated as numbers and proportions, %. The upper rows are non-segregated distributions of MetS components, one or two risk factors are included and overlapping can happen; the lower rows are segregated by each signal and combinations, all individual conditions are listed. Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL cholesterolemia; HBP, high blood pressure; Hyper-TG, hypertriglyceridemia; COB, central obesity.
- **χ2 tests were conducted for categorical variables between groups with/without MetS outcome.
